InvestorsHub Logo
Followers 155
Posts 2622
Boards Moderated 0
Alias Born 01/29/2004

Re: georgejjl post# 329826

Monday, 09/13/2021 12:15:20 PM

Monday, September 13, 2021 12:15:20 PM

Post# of 460290
Placebo stuff again?

NO BLINDING OF THE Open Label Extension Study


Aw, that's just awful news.

Everyone knows that if patients in a clinical trial of a drug actually don't know if the pill they are taking is real, by the placebo effect they will mentally work up and produce otherwise invalid clinical results.

So, in the Open Label Extension (OLE) study, any good results will just have to be attributed to the placebo effect, not blarcamesine itself.

I know of the placebo effect, in Alzheimer's myself. My father, an accomplished public accountant, began to have trouble remembering things. My mother, an experienced geriatric nurse, saw things exactly. Dad had Alzheimer's setting in.

Because of her medical contacts, mother enrolled dad in one of the FDA-approved clinical studies of Aricept (donepezil) at a nearby medical school. Not long into the study, mother said that whatever this new drug was, if dad was in the experimental (drug-taking) arm of the study, it was producing no therapeutic results. Dad's cognition continued to decline unabated through the entire long trial period.

For me, in this particular incident, it proved one of two things: a) if my dad was taking donepezil, it failed; or b) if he wasn't, was in the control arm of the study, taking a disguised starch pill, he was unable to generate any sort of placebo effect. By the force of mental willpower ("I'm taking a powerful new drug that will help!"), he was unable to reverse any Alzheimer's symptom. There can be no placebo effect in Alzheimer's. Determined or hoped-for willpower can't fix the biochemical anomalies of the neurons in Alzheimer's.

So, let's watch; to see how the OLE results are interpreted by the news media. Will they be attributed to blarcamesine itself, or to the placebo effect?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News